Immuneering (IMRX) announced the appointment of Thomas Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering’s Strategic Advances and Positive Outlook Boost Buy Rating and Price Target
- Immuneering to announce updated data from Phase 2a trial of Atebimetinib + mGnP
- Immuneering files to sell 9.18M shares of Class A common stock for holders
- Immuneering’s Strategic Partnerships and Promising Clinical Developments Justify Buy Rating
- Immuneering announces clinical supply agreement with Eli Lilly